Zhang S Y, Wang Y
Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.
Zhonghua Zhong Liu Za Zhi. 2021 Jan 23;43(1):98-103. doi: 10.3760/cma.j.cn112152-20191218-00819.
Small cell lung cancer (SCLC) is a neuroendocrine tumor, which accounts for about 15% of all lung cancers. SCLC is characterized by rapid growth and tendency to widespread metastasis at the initial stage. Although high response rates to first-line chemotherapy are observed, most patients relapse less than few months. In the past 5 years, some clinical trials found that the immune checkpoint inhibitors (ICIs) were effective in SCLC, especially programmed cell death 1/ligand 1 (PD-1/L1). Given this situation, the treatment patterns of SCLC have changed. This article briefly reviews the researches and studies of ICIs in the treatment of SCLC to provide reference to the clinicians.
小细胞肺癌（SCLC）是一种神经内分泌肿瘤，约占所有肺癌的15%。SCLC的特点是生长迅速，在疾病初期即有广泛转移的倾向。尽管一线化疗的缓解率较高，但大多数患者在数月内就会复发。在过去5年中，一些临床试验发现免疫检查点抑制剂（ICIs）对SCLC有效，尤其是程序性细胞死亡蛋白1/配体1（PD-1/L1）。鉴于此，SCLC的治疗模式发生了改变。本文简要综述了ICIs治疗SCLC的研究，为临床医生提供参考。
